The Evidence Behind KP⁷

Kaempferia parviflora (200mg, 5% PMFs)

The primary human trial is Wattanathorn et al. (2012), conducted at Chiang Mai University. Randomised, double-blind, placebo-controlled. Twelve resistance-trained male participants supplemented 180mg of Kaempferia parviflora extract or placebo daily for 8 weeks. The trial demonstrated statistically significant improvements in grip strength and physical fitness parameters in the KP group versus placebo.

The population (resistance-trained males) is directly relevant to pre-workout applications. This is not a trial conducted on sedentary individuals where any intervention produces results. These are trained subjects for whom measurable performance improvement is harder to achieve. The KP⁷ dose of 200mg exceeds the 180mg used in this trial.

Mechanistic support comes from two additional lines of evidence: Temkitthawon et al. demonstrated PDE5 inhibitory activity of PMFs from Kaempferia parviflora in enzyme assays; Promthep et al. examined eNOS activation and endothelial function markers. Together, these establish the mechanism that explains the functional outcome in the Wattanathorn trial.

L-Citrulline (4,000mg)

L-Citrulline is a non-essential amino acid converted in the kidney to L-arginine, which serves as the substrate for eNOS. Unlike direct L-arginine supplementation, Citrulline bypasses first-pass hepatic extraction and produces a more sustained increase in plasma arginine levels.

The evidence base is well-established. Pérez-Guisado and Jakeman (2010) demonstrated that 8g of Citrulline malate improved high-intensity exercise performance and reduced muscle soreness ratings versus placebo in resistance-trained males. Curis et al. (2007) confirmed the arginine-raising kinetics. Bailey et al. (2015) showed acute effects on vascular function and exercise tolerance.

The clinically studied minimum effective dose ranges from 3,000mg to 6,000mg in published trials. At 4,000mg per serving, KP⁷ exceeds the lower threshold of the studied range. Combined with Kaempferia parviflora's PDE5-inhibitory action, the Citrulline-generated NO signal is extended rather than metabolised away; the combination is mechanistically complementary.

Caffeine + L-Theanine (200mg + 200mg)

The 1:1 combination of caffeine and L-Theanine is one of the most replicated findings in cognitive performance research. Haskell et al. (2008) demonstrated that 100mg caffeine + 50mg L-Theanine produced better accuracy on attention tasks than either compound alone, with reduced susceptibility to distracting stimuli. Owen et al. (2008) replicated these findings with a focus on headache and tiredness reduction alongside improved alertness.

L-Theanine attenuates the anxiety and jitteriness associated with caffeine, likely via GABA-ergic modulation, while preserving the alertness and focus-enhancing effects. The net result is a qualitatively smoother stimulant experience: sharper focus without the edge, sustained energy without the crash.

200mg caffeine is a considered dose relative to the category norm of 300–400mg. Higher caffeine loads produce a more pronounced spike and a correspondingly more pronounced decline; the crash is a feature that high-stimulant brands do not list on the label. At 200mg paired 1:1 with L-Theanine, the effect curve is flatter, longer, and more functional. You do not collapse after the session.

Rhodiola rosea (150mg, 3% rosavins / 1% salidroside)

Rhodiola rosea is a Scandinavian and central Asian adaptogen with a published evidence base on fatigue resistance and physical endurance. Noreen et al. (2013) demonstrated reduced perceived exertion and improved endurance capacity with Rhodiola supplementation versus placebo. De Bock et al. (2004) found acute Rhodiola administration improved endurance exercise performance in trained males.

The active constituents are rosavins and salidrosides. Standardisation to 3% rosavins / 1% salidroside matches the extract specification used in the key clinical trials; this is not arbitrary. Off-specification extracts with lower standardisation levels cannot be benchmarked against the published evidence.

150mg at this standardisation is appropriate for a multi-ingredient formula where Rhodiola supports the overall fatigue-resistance profile alongside the primary vascular mechanism. It is not the hero compound; it is a supporting active doing a specific job.

Betaine Anhydrous (2,500mg)

Betaine (trimethylglycine) is a naturally occurring osmolyte found in beets and spinach. It functions as a methyl donor in one-carbon metabolism and as a cellular osmolyte, helping cells maintain hydration status under osmotic stress. Its performance applications relate to both mechanisms: methyl donation supports creatine synthesis pathways; cellular osmolyte function may enhance muscle cell volume and function under load.

The evidence is most consistent at the 2,500mg dose. Trepanowski et al. (2011) used 2,500mg and found improvements in power output and body composition over six weeks. Craig (2004) established the osmolyte and methyl donor mechanisms. 2,500mg is the dose used in most published trials and is the standard for this ingredient.

Bioperine (5mg, 95% piperine)

Piperine, the active alkaloid in black pepper, inhibits cytochrome P450 3A4 and P-glycoprotein, two key drug-metabolism enzymes responsible for first-pass clearance of many compounds. By transiently inhibiting these enzymes, piperine increases the bioavailability of co-administered compounds. Shoba et al. (1998) demonstrated a 2,000% increase in curcumin bioavailability with co-administration of 20mg piperine; effects on other compounds are compound-specific but the mechanism is well established.

5mg at 95% piperine standardisation is the standard clinical dose. It is included in KP⁷ to support maximum absorption of the active ingredients, particularly the Kaempferia parviflora PMFs, which are lipophilic and subject to first-pass extraction.

No beta-alanine

Beta-alanine is a carnosine precursor that increases intramuscular carnosine, which buffers hydrogen ions during high-intensity exercise. The performance evidence at 3.2–6.4g daily over several weeks is modest and inconsistent. More importantly: it causes the tingling (paraesthesia) sensation familiar to anyone who has taken a mainstream pre-workout. This sensation is frequently presented as evidence that the product is “working.” It is not. It is a side effect of peripheral nerve activation, a sensory signal with no causal link to performance. KP⁷ does not include it because KP⁷ does not need the theatre.

200mg caffeine, not 300mg

The category standard is 300–400mg caffeine. At those doses, caffeine produces a sharper initial CNS spike and a correspondingly sharper crash 2–3 hours later. The crash impairs post-session function and sleep quality, particularly for afternoon training sessions. At 200mg paired with 200mg L-Theanine, the curve is flatter, longer, and more functional. The 1:1 combination is specifically supported by the evidence on sustained cognitive performance without the crash mechanism. This is not a weaker formula. It is a better-designed one.